Skip to content

GIP and GLP-1 in Type 1 Diabetes

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01739283
Enrollment
10
Registered
2012-12-03
Start date
2012-07-31
Completion date
2013-11-30
Last updated
2015-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypoglycemia

Brief summary

Investigation of Glucose-dependent Insulinotropic Polypeptide (GIP) effects at hyper and hypoglycemia in type 1 diabetes.

Interventions

OTHERGIP
OTHERGLP-1
OTHERSaline

Sponsors

University of Copenhagen
CollaboratorOTHER
Mikkel Christensen
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
MALE
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

• Diagnosed with type 1 diabetes (WHO criteria)

Exclusion criteria

* HbA1c \> 9 % * Liver disease (ALAT/ASAT \> 2 x upper normal limit) * Diabetic nephropathy (s-creatinine \> 130 µM or albuminuria) * Proliferative diabetic retinopathy (anamnestic) * Severe arteriosclerosis or heart failure (NYHA group III or IV) * Anemia * treatment with medication not applicable to pause for 12 hours * C-peptide increase after 50 g iv arginine

Design outcomes

Primary

MeasureTime frame
plasma glucagon area under curve valuesapprox. 15 minutes intervals, time 0 to 120 min

Secondary

MeasureTime frame
plasma gut hormones and nutrients (absolute, incremental and area under curve values)approx. 15 minutes intervals, time 0 to 120 min

Other

MeasureTime frame
Glucose and glycerol tracer kineticsapprox. 15 minutes intervals, time 0 to 120 min
glucose (g/kg body weight) needed to be infuse to keep clampapprox. 15 minutes intervals, time 0 to 120 min

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026